Page last updated: 2024-09-04

pralnacasan and maprotiline

pralnacasan has been researched along with maprotiline in 2 studies

Compound Research Comparison

Studies
(pralnacasan)
Trials
(pralnacasan)
Recent Studies (post-2010)
(pralnacasan)
Studies
(maprotiline)
Trials
(maprotiline)
Recent Studies (post-2010) (maprotiline)
190793321159

Protein Interaction Comparison

ProteinTaxonomypralnacasan (IC50)maprotiline (IC50)
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)0.078
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)0.03
Muscarinic acetylcholine receptor M2Homo sapiens (human)1.927
Muscarinic acetylcholine receptor M4Homo sapiens (human)0.413
Cytochrome P450 3A4Homo sapiens (human)4.322
Muscarinic acetylcholine receptor M5Homo sapiens (human)0.16
Alpha-2A adrenergic receptorHomo sapiens (human)1.824
Muscarinic acetylcholine receptor M1Homo sapiens (human)0.593
D(2) dopamine receptorHomo sapiens (human)3.463
Alpha-2B adrenergic receptorHomo sapiens (human)0.292
Alpha-2C adrenergic receptorHomo sapiens (human)3.044
Muscarinic acetylcholine receptor M3Homo sapiens (human)0.473
D(1A) dopamine receptorHomo sapiens (human)0.373
Sodium-dependent noradrenaline transporter Homo sapiens (human)0.03
Histamine H2 receptorHomo sapiens (human)0.4
Alpha-1D adrenergic receptorHomo sapiens (human)0.397
5-hydroxytryptamine receptor 2AHomo sapiens (human)0.064
5-hydroxytryptamine receptor 2CHomo sapiens (human)0.078
Histamine H1 receptorHomo sapiens (human)0.0088
D(3) dopamine receptorHomo sapiens (human)0.645
5-hydroxytryptamine receptor 2BHomo sapiens (human)0.336
5-hydroxytryptamine receptor 6Homo sapiens (human)0.892
Voltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)10
Sodium-dependent dopamine transporter Homo sapiens (human)2.91

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1

Reviews

1 review(s) available for pralnacasan and maprotiline

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

1 other study(ies) available for pralnacasan and maprotiline

ArticleYear
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011